NMRA
Income statement / Annual
Last year (2025), Neumora Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Neumora Therapeutics Inc.'s net income was -$236.93 M.
See Neumora Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$5.00 M
|
$0.00
|
$668.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$5.00 M
|
$0.00
|
-$668.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$176.07 M
|
$200.93 M
|
$142.72 M
|
$104.75 M
|
$212.78 M
|
$87.13 M
|
| General & Administrative Expenses |
$60.09 M
|
$62.54 M
|
$45.48 M
|
$31.12 M
|
$24.55 M
|
$8.39 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
-$668.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$60.09 M
|
$62.54 M
|
$44.81 M
|
$31.12 M
|
$24.55 M
|
$8.39 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$236.16 M
|
$263.46 M
|
$187.53 M
|
$135.87 M
|
$237.32 M
|
$95.52 M
|
| Cost And Expenses |
$241.16 M
|
$263.46 M
|
$188.19 M
|
$135.87 M
|
$237.32 M
|
$95.52 M
|
| Interest Income |
$8.34 M
|
$19.93 M
|
$16.61 M
|
$4.56 M
|
$0.00
|
$0.00
|
| Interest Expense |
$3.22 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$208.00 K
|
$631.00 K
|
$668.00 K
|
$594.00 K
|
$538.00 K
|
$105.00 K
|
| EBITDA |
-$233.37 M |
-$242.98 M |
-$234.99 M |
-$130.31 M |
-$236.77 M |
-$95.41 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$4.36 M
|
$19.86 M
|
-$47.46 M
|
$4.97 M
|
$11.00 K
|
-$3.75 M
|
| Income Before Tax |
-$236.80 M
|
-$243.61 M
|
-$235.66 M
|
-$130.90 M
|
-$237.31 M
|
-$99.27 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$130.00 K
|
$178.00 K
|
$268.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$236.93 M
|
-$243.79 M
|
-$235.93 M
|
-$130.90 M
|
-$237.31 M
|
-$99.27 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.45 |
-1.53 |
-1.49 |
-0.86 |
-1.56 |
-0.65 |
| EPS Diluted |
-1.45 |
-1.53 |
-1.49 |
-0.86 |
-1.56 |
-0.65 |
| Weighted Average Shares Out |
$163.39 M
|
$159.38 M
|
$158.83 M
|
$151.95 M
|
$151.95 M
|
$151.95 M
|
| Weighted Average Shares Out Diluted |
$163.39 M
|
$159.38 M
|
$158.83 M
|
$151.95 M
|
$151.95 M
|
$151.95 M
|
| Link |
|
|
|
|
|
|
